A cereal to combat Alzheimer’s? Scientists have obtained surprising laboratory results

A new laboratory study has shown that polyphenolic extracts from black and red sorghum may reduce the formation of toxic amyloid-beta clumps — one of the proteins associated with the development of Alzheimer’s disease. In cell-based experiments, these substances also helped cells to survive, reduced oxidative stress and improved mitochondrial function. The study has been published in the journal Nutrients.

But the key point must be made straight away: this is not a treatment, not a medicine and not a recommendation to eat sorghum ‘for dementia’. The results were obtained solely in the laboratory — using a cell model and computer analysis. There is still a long way to go before studies on animals and humans can be carried out.

What is sorghum and why is it of interest to Ukraine?

Sorghum is an ancient cereal crop. It is also well known in Ukraine: people most often refer to grain sorghum, sweet sorghum, broomcorn sorghum or fodder varieties. For Ukrainian farmers, this crop is of particular interest due to its resistance to heat and drought, which is why it is increasingly being discussed in the context of climate change and arid regions.

For the general public, sorghum is not as familiar as wheat, buckwheat, rice or maize. However, it is a distinct cereal that is used worldwide for food, in livestock farming and in industry.

The new study does not claim that ordinary sorghum porridge can treat Alzheimer’s disease. The scientists were not studying the finished dish, but rather extracts of polyphenols — plant compounds found in the grain, particularly in pigmented varieties.

What exactly did the scientists investigate?

The researchers took several varieties of sorghum — black, reddish-brown and red — and extracted polyphenols from them. They then tested how these substances affected Aβ42, a form of amyloid-beta that tends to form toxic protein clumps. Such clumps are associated with the pathological processes involved in Alzheimer’s disease.

The results were striking: the sorghum extracts reduced Aβ42 aggregation by 67–76 per cent and decreased the number of toxic oligomers. Put simply, in a laboratory test tube, the substances derived from sorghum prevented the protein from clumping together into dangerous structures.

The researchers then moved on to a cellular model. They used cells that produce toxic amyloid-beta and therefore mimic some of the processes associated with Alzheimer’s disease. When the cells were treated with sorghum extracts, their survival rate increased by more than 70%, and mitochondrial activity by more than 80%.

Why this is important

Alzheimer’s disease is the most well-known cause of dementia. It is not linked to a single process, but to a whole range of abnormalities: the accumulation of amyloid-beta, changes in tau protein, inflammation, oxidative stress, mitochondrial damage and the death of nerve cells. Recent reviews emphasise that amyloid-beta and tau remain key pathological hallmarks of the disease, but the overall picture of the condition is far more complex.

This is precisely why scientists are interested in substances that can act on several mechanisms simultaneously. In the case of sorghum, researchers observed not only an effect on amyloid-beta, but also a reduction in oxidative stress, improved mitochondrial function and changes in the activity of genes associated with inflammation and cell death.

This means that sorghum is not a ‘medicine’, but an interesting candidate for further research.

In simple terms: what happened

To put it as simply as possible, the scientists extracted substances from sorghum and tested them against one of the ‘harmful’ proteins associated with Alzheimer’s disease.

In the laboratory, these substances:

• reduced the clumping of amyloid-beta;
• helped cells survive better under toxic conditions;
• reduced signs of cellular stress;
• supported the functioning of mitochondria — the cells’ energy ‘powerhouses’.

However, none of this took place in the human brain, but in a laboratory model. This is an early stage of research.

Why you shouldn’t rush out to buy sorghum ‘for your brain’

The biggest mistake would be to treat this research as medical advice. You mustn’t do that.

Firstly, the scientists were studying concentrated extracts, not a normal portion of porridge, bread or sorghum flour.

Secondly, a cell in a laboratory is not the same as the human body. In real life, substances must be digested, absorbed, metabolised, enter the bloodstream and then — in the case of the brain — cross the blood-brain barrier.

Thirdly, Alzheimer’s disease develops over many years and depends on a multitude of factors. Even a strong laboratory effect against a single protein does not mean that a product will be able to prevent or treat dementia.

The study’s authors themselves point out that further in vivo studies – that is, on living organisms – are needed to test the efficacy and practical potential of sorghum polyphenols.

Why the discovery is still interesting

Despite its limitations, the study is important for two reasons.

Firstly, it demonstrates that common agricultural crops may contain compounds with unexpected biological activity. Sorghum is not an exotic, rare product, but a widespread cereal grown in various countries, including Ukraine.

Secondly, this line of research fits well with the current search for additional strategies to combat neurodegenerative diseases. Scientists are increasingly studying not only medicines but also dietary compounds that may influence inflammation, oxidative stress and cellular defence.

This is not a substitute for medicine. However, in the future, such data may help in the development of functional foods, supplements or new molecules for research.

Background

Dementia remains one of the greatest challenges facing an ageing society. According to WHO estimates, tens of millions of people worldwide are living with dementia, and the number of cases is set to rise as the population ages.

This is precisely why any new approaches to studying Alzheimer’s disease attract considerable interest. But there is a long road between a laboratory discovery and an actual treatment: first, animal trials are needed, followed by clinical trials to test safety, dosages and actual efficacy.

The story of sorghum represents precisely such a first step. It is interesting, but does not yet constitute a medical breakthrough.

Source

Study: Rasheed A. Abdulraheem et al., “Neuroprotective Effects of Sorghum Polyphenol in Alzheimer’s Disease: In Vitro and In Silico Analyses”, Nutrients, 2026.